Dr. David Marshall Salvay, MD, PhD

Dr. Salvay practices at Newport Bay Surgery Center in Newport Beach, California.

Dr. Salvay's NPI, 1700173655, was assigned on June 29, 2011. Dr. Salvay graduated from Feinberg School of Medicine in 2011. Dr. Salvay holds California license A144341.

Dr. Salvay's primary practice is Newport Bay Surgery Center, at 3333 W Coast Highway, Suite 100, Newport Beach, CA 92663. The practice phone is (949) 645-6272.

Dr. Salvay's primary practice is Newport Bay Surgery Center in Newport Beach, California. Dmand AI also links Dr. Salvay to 3 medical groups and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Salvay practices, 2 sites in all. Vendor and product names are available with a free account.

Ophthalmology is Dr. Salvay's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Salvay is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Salvay's licenses on file in 6 states: California, Texas, Washington, Maine, Missouri and Illinois.

Dmand AI lists age-related macular degeneration, cataract, cataract surgery with lens implant, conjunctivitis, dry eye, eyelid inflammation, glaucoma and glaucoma surgery among the conditions Dr. Salvay treats.

CMS data shows 1,975 Medicare services from Dr. Salvay across 15 procedure codes in 2024, for 497 Medicare patients. Medicare paid $183,986 for them.

CMS counts 497 Medicare patients who saw Dr. Salvay in 2024. The largest group is 75 to 84, with 222 patients. 75% of them have high cholesterol, and 70% have high blood pressure. Their average risk score is 1.10, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Salvay's median patient age at 76, with 61% women.

In 2024, Dr. Salvay wrote 1,751 Medicare Part D claims for 444 patients. 67% of them were for generic drugs. CMS names the drug for 1,691 of them, across 21 drugs with 11 or more claims each, at $114,141 in total drug cost. In 2023, CMS named 1,686 claims across 19 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Salvay for performance year 2024, reported individually. Dr. Salvay accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 189 procedures of cataract surgery by Dr. Salvay, more than 83% of the clinicians it reports for that procedure.

Dmand AI links 14 papers to Dr. Salvay, published from 2005 to 2013. 2010 was the busiest year, with 2. The most frequent topics are Tissue Scaffolds, Gene Transfer Techniques and Biocompatible Materials. Dr. Salvay's most frequent co-authors are Gregory A. Dumanian, MD, Julia Grace Harris, MD and Marisa Sue Klein-Gitelman, MD, MPH.

CMS Open Payments shows 127 general payments to Dr. Salvay from 35 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 94% of the total. Johnson & Johnson Surgical Vision, Inc. paid the most, $1,700. It also lists 1 research payment totaling $1,200 in 2018.

Dmand AI lists 19 awards for Dr. Salvay, most recently American Academy of Ophthalmology Advocacy Ambassador in 2014. Dr. Salvay serves on Medical Quality Review Committee.

Dr. Salvay graduated from Feinberg School of Medicine in 2011. Dr. Salvay is a member of AAO, ASCRS and Orange County Society of Ophthalmology.

Dr. Salvay is in network with 16 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.